Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
12/7/2023 | $15.00 | Hold → Buy | Jefferies |
8/7/2023 | $30.00 | Hold → Buy | Maxim Group |
7/22/2022 | Outperform → Neutral | Robert W. Baird | |
7/22/2022 | Buy → Hold | Jefferies | |
7/22/2022 | Outperform → Mkt Perform | William Blair |
Vistagen CEO Shawn Singh; The Goldie Hawn Foundation Founder Goldie Hawn; and MindUP students to ring the Nasdaq Closing Bell on October 10, 2024 Vistagen and The Goldie Hawn Foundation join forces to raise awareness around the roles of mindfulness and pioneering neuroscience in mental health Vistagen (NASDAQ:VTGN), a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development of groundbreaking therapies for psychiatric disorders based on nose-to-brain neurocircuitry, and The Goldie Hawn Foundation's MindUP, a neuroscience-based preventative mental health program for youth, along with children from New York City schools utilizing MindUP, will join toget
Anderson succeeds Jerrold Dotson who is retiring after a distinguished decade-long career with Vistagen Vistagen (NASDAQ:VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced the appointment of Cindy Anderson as Chief Financial Officer (CFO), effective August 21, 2023. Ms. Anderson will succeed Jerrold Dotson, whose planned retirement was announced in July of this year. "We are delighted to welcome Ms. Anderson, an experienced and highly accomplished finance professional, to our team," said Shawn Singh, Chief Executive Officer of V
Annual Meeting to resume October 28, 2022 to vote on Proposal No. 5 to provide Vistagen's Board of Directors the option to implement a future reverse stock split of the Company's issued and outstanding common stock, if necessary to maintain the Company's listing on the Nasdaq Capital Market, and Proposal No. 6 to allow for an amendment to the Company's Bylaws Vistagen Therapeutics, Inc. (NASDAQ:VTGN) (the Company), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced results of voting and the partial adjournment of the Company's 2022 Annua
Jefferies upgraded VistaGen from Hold to Buy and set a new price target of $15.00
Maxim Group upgraded VistaGen from Hold to Buy and set a new price target of $30.00
Robert W. Baird downgraded VistaGen from Outperform to Neutral
Fasedienol U.S. registration-directed PALISADE Phase 3 Program for acute treatment of social anxiety disorder progressing PALISADE-3 and PALISADE-4 Phase 3 trials initiated and underway Vistagen (NASDAQ:VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today reported financial results for its fiscal year 2025 second quarter ended September 30, 2024, and provided a corporate update. "We initiated our PALISADE-4 Phase 3 trial during our second quarter, achieving yet another significant milestone in our fasedienol U.S. registration-directed Phase 3 Program for the acute treatment of social anxiety disorder," said Shawn Singh, Ch
Vistagen (NASDAQ:VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced it will host a conference call and webcast on Thursday, November 7, 2024, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2025 second quarter ended September 30, 2024, and provide a corporate update. Event: Vistagen Fiscal Year 2025 Second Quarter Corporate Update Conference Call Date: Thursday, November 7, 2024 Time: 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) US Dial-in (Toll-free): 1-800-717-1738 TOLL/International Dial-in: 1-646-307-1865 Conference ID: 1196845 Webcast: https://viavid.webcasts.com/s
PALISADE Phase 3 Program for the acute treatment of Social Anxiety Disorder progressing on track Vistagen (NASDAQ:VTGN), a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today reported financial results for its fiscal year 2025 first quarter ended June 30, 2024, and provided a corporate update. "Building on the success of our PALISADE-2 Phase 3 trial of fasedienol, our rapid-onset, non-systemic pherine nasal spray for the acute treatment of social anxiety disorder, our top priority remains driving forward our
8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)
10-Q - Vistagen Therapeutics, Inc. (0001411685) (Filer)
8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)
4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
Fasedienol U.S. registration-directed PALISADE Phase 3 Program for acute treatment of social anxiety disorder progressing PALISADE-3 and PALISADE-4 Phase 3 trials initiated and underway Vistagen (NASDAQ:VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today reported financial results for its fiscal year 2025 second quarter ended September 30, 2024, and provided a corporate update. "We initiated our PALISADE-4 Phase 3 trial during our second quarter, achieving yet another significant milestone in our fasedienol U.S. registration-directed Phase 3 Program for the acute treatment of social anxiety disorder," said Shawn Singh, Ch
Vistagen (NASDAQ:VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced that it will present posters highlighting new prevalence data for social anxiety disorder (SAD), an indication for which fasedienol, its lead intranasal pherine product candidate, is in U.S. registration-directed Phase 3 development for the acute treatment of the disorder, and two additional non-systemic intranasal pherine product candidates in its neuroscience pipeline, itruvone in Phase 2 development for major depressive disorder and hormone-free PH80 in Phase 2 development for the management of vasomotor symptoms (hot flashes) due to menopause,
Vistagen (NASDAQ:VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced it will host a conference call and webcast on Thursday, November 7, 2024, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2025 second quarter ended September 30, 2024, and provide a corporate update. Event: Vistagen Fiscal Year 2025 Second Quarter Corporate Update Conference Call Date: Thursday, November 7, 2024 Time: 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) US Dial-in (Toll-free): 1-800-717-1738 TOLL/International Dial-in: 1-646-307-1865 Conference ID: 1196845 Webcast: https://viavid.webcasts.com/s
SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)
SC 13G - Vistagen Therapeutics, Inc. (0001411685) (Subject)
SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)
Cash and cash equivalents were $119.2 million as of March 31, 2024.
PH15 nasal spray demonstrates statistically significant efficacy versus placebo and caffeine in a placebo-controlled Phase 2A pilot study in sleep-deprived participantsPH15 was safe and well-tolerated with an adverse event profile similar to placeboVistagen (NASDAQ:VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced positive results from a Phase 2A pilot study of PH15, an investigational pherine nasal spray, for improvement of psychomotor impairment caused by mental fatigue. PH15 demonstrated a statistically significant improvement in reaction time compared to placeb